What is Epidermodysplasia Verruciformis?

Epidermodysplasia verruciformis (EV) is a rare, lifelong hereditary skin disorder characterized by an abnormal and profound susceptibility to infection by specific strains of human papillomavirus (HPV). First described by Lewandowsky and Lutz in 1922, the condition results in the uncontrolled proliferation of flat wart-like lesions and scaly plaques across large areas of the skin, most prominently on sun-exposed surfaces. In severe cases, the sheer volume and woody texture of these growths have given rise to the colloquial name “tree man disease,” though this term is not used clinically.

Epidermodysplasia verruciformis is of particular importance in dermatology not only because of its dramatic cutaneous presentation but also because of the significant risk of malignant transformation it carries. Affected individuals have a substantially elevated lifetime risk of developing non-melanoma skin cancers, particularly squamous cell carcinoma, in lesion-bearing areas exposed to ultraviolet radiation.

Causes and Genetic Basis of Epidermodysplasia Verruciformis

Epidermodysplasia verruciformis is primarily an autosomal recessive condition, meaning that an affected individual must inherit mutated copies of the relevant gene from both parents. The disorder is most commonly caused by loss-of-function mutations in the EVER1 (also known as TMC6) or EVER2 (also known as TMC8) genes, both located on chromosome 17q25. These genes encode transmembrane channel-like proteins that are expressed in keratinocytes and play a role in regulating zinc homeostasis within cells. Zinc is essential to the function of several transcription factors that HPV exploits to replicate. When EVER1 or EVER2 are non-functional, keratinocytes become permissive hosts for EV-associated HPV types, allowing viral replication to proceed unchecked.

More recently, mutations in other genes including RHOH, MST1, CORO1A, and STING1 have been identified in a subset of EV patients who do not carry EVER1/EVER2 mutations, indicating that the genetic architecture of epidermodysplasia verruciformis is broader than initially appreciated. An acquired form of the condition is also recognized, occurring in individuals with severe immunodeficiency — such as those with HIV/AIDS, organ transplant recipients on immunosuppressive therapy, or patients with primary immunodeficiency syndromes — who lack the immunological capacity to control HPV infection adequately.

HPV Types in Epidermodysplasia Verruciformis

Unlike the common wart-causing HPV types that infect the general population (such as HPV-1, HPV-2, and HPV-4), epidermodysplasia verruciformis is associated with a distinct group of HPV genotypes collectively referred to as “EV-specific” or “beta-HPV” types. The most clinically significant of these are HPV-5 and HPV-8, which together are detected in the majority of EV-associated squamous cell carcinomas. Dozens of additional EV-associated HPV types have been identified, including HPV-9, HPV-12, HPV-14, HPV-15, HPV-17, HPV-19 through HPV-25, and many others. Interestingly, these beta-HPV types are present at low levels on the skin of healthy individuals worldwide but cause disease only in those with the EV-specific immune defect.

Clinical Features and Symptoms

Epidermodysplasia verruciformis typically manifests in childhood or adolescence, though onset can occasionally be delayed into early adulthood. The skin findings are widespread and polymorphic. Two main types of lesions are recognized. The first type resembles flat warts (verruca plana): flat-topped, slightly scaly, reddish-brown or hypopigmented papules distributed across the dorsa of the hands, forearms, face, and neck. The second type consists of pityriasis versicolor-like macules and plaques with a fine scale, often seen on the trunk. Over time, lesions may become confluent, thickened, and more numerous.

In addition to these primary lesions, patients with epidermodysplasia verruciformis develop seborrheic keratosis-like plaques and, in sun-exposed areas particularly after the third or fourth decade of life, premalignant lesions including actinic keratoses and Bowen’s disease (squamous cell carcinoma in situ). Frank invasive squamous cell carcinoma develops in 30 to 60 percent of EV patients, typically appearing in areas of chronic sun exposure such as the face, scalp, and dorsal hands. Crucially, despite their aggressive local behavior, these EV-associated squamous cell carcinomas rarely metastasize — a somewhat unusual feature that distinguishes them from immunosuppression-related carcinomas in transplant patients.

Patients with epidermodysplasia verruciformis do not generally suffer from increased susceptibility to other infections, distinguishing the condition from broader primary immunodeficiency disorders. Cell-mediated immunity is selectively impaired with respect to EV-HPV types, while responses to other pathogens remain largely intact.

Histopathology

Biopsy of EV lesions reveals characteristic histological features that aid in diagnosis. The epidermis shows acanthosis (thickening) with large, pale-staining keratinocytes in the upper layers of the spinous and granular zones. These cells, sometimes called “EV cells,” have abundant pale blue-grey cytoplasm, irregular nuclei, and perinuclear halos. They represent keratinocytes productively infected with EV-HPV. Koilocytes (cells with cytoplasmic clearing and nuclear atypia characteristic of HPV infection) may also be present. In malignant or premalignant lesions, features of keratinocytic dysplasia and carcinoma in situ may be superimposed on these EV-specific changes.

Diagnosis of Epidermodysplasia Verruciformis

The diagnosis of epidermodysplasia verruciformis is based on the combination of clinical presentation, family history, histopathological findings, and virological confirmation. Skin biopsy demonstrating EV cells in the appropriate clinical context is strongly suggestive. HPV typing using polymerase chain reaction (PCR) techniques on lesional skin tissue can identify the specific EV-HPV genotypes present, further supporting the diagnosis. Genetic testing for EVER1 and EVER2 mutations is available and confirms the hereditary form of the disease when positive. Immunological workup including lymphocyte subset analysis and functional assays may be indicated to exclude acquired immunodeficiency as an underlying cause in atypical presentations.

Treatment of Epidermodysplasia Verruciformis

There is currently no curative treatment for epidermodysplasia verruciformis. Management is focused on three main goals: controlling existing lesions, preventing malignant transformation, and providing regular surveillance for skin cancer.

Antiviral therapy with systemic acyclovir is ineffective against HPV. Retinoids, particularly acitretin and isotretinoin, have demonstrated partial efficacy in reducing the number and size of wart-like lesions in some patients with epidermodysplasia verruciformis and represent one of the primary systemic treatment options. However, lesions tend to recur upon cessation of therapy, and long-term retinoid use carries significant side effects including teratogenicity, hepatotoxicity, and hyperlipidaemia.

Interferon-alpha has been used both systemically and intralesionally with variable results, occasionally producing temporary improvement but generally not sustained remission. Imiquimod, a topical immune response modifier that stimulates innate immunity and triggers local antiviral responses, has been tried in individual cases with limited evidence of benefit.

Destructive therapies including cryotherapy, laser ablation (CO2 or Er:YAG), electrosurgery, and surgical excision are used to treat individual lesions or areas of premalignant change, particularly actinic keratoses and Bowen’s disease. Photodynamic therapy (PDT) with topical photosensitizers such as aminolevulinic acid has also been employed as a field therapy for widespread superficial lesions. For invasive squamous cell carcinoma, surgical excision with appropriate margins remains the standard of care.

Strict and lifelong sun protection is an essential component of EV management. Patients should be counseled on the regular use of high-factor broad-spectrum sunscreens (SPF 50+), protective clothing, wide-brimmed hats, and avoidance of peak ultraviolet radiation hours. Ultraviolet radiation acts as a co-carcinogen in EV-associated malignant transformation, and minimizing cumulative UV exposure is one of the most effective strategies available to reduce skin cancer risk in these patients.

Surveillance and Long-Term Management

Given the high lifetime risk of squamous cell carcinoma, patients with epidermodysplasia verruciformis require regular and indefinite dermatological surveillance, typically every three to six months. Full-body skin examinations should assess for new or changing lesions, and any suspicious areas should be biopsied promptly. Dermoscopy can assist in identifying early malignant or premalignant change. Patient education regarding self-skin examination is important so that interval changes are detected early between clinical visits.

Genetic counseling is appropriate for affected individuals and their families, as the autosomal recessive inheritance pattern means that siblings of an affected proband have a 25% chance of also being affected, and carrier parents have a 50% chance of passing the mutation to each child. Prenatal testing is theoretically possible where pathogenic mutations have been identified.

Prognosis

The prognosis of epidermodysplasia verruciformis is highly variable and depends primarily on the degree of malignant transformation and the timeliness of its management. Patients who adhere to rigorous sun protection and undergo regular surveillance generally have a better long-term outcome. The squamous cell carcinomas arising in EV have a lower tendency to metastasize than conventional squamous cell carcinomas, which is a relatively favorable feature; however, local destruction and disfigurement from multiple carcinomas over a lifetime can be substantial. Morbidity is significant due to the chronicity of the condition, the psychological impact of widespread disfiguring skin lesions, and the lifelong burden of disease management and monitoring.

Active research into gene therapy, RNA interference strategies, and HPV vaccination approaches for EV-specific strains offers hope for more effective future interventions, but no such therapies are currently available in routine clinical practice.